PUBLIC COMPANY
save$TYRATyra Biosciences, Inc.
$TYRA21.98+2.47%Carlsbad, CA, USupdated 2h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Phase 11Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
- phase1Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
- phase2A Study of TYRA-300 in Children With Achondroplasia: BEACH301
- phase2Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- phase2Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
- phase1Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- phase1A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 16, 26grantDable Habib J · director44,400 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer successPlus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…endpoints · 15d ago
- Tyra shares slip as bladder cancer responses fall short of investor expectationsDespite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.biospace · 19d ago
- Tyra disappoints investors with bladder cancer dataRemission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.biopharma_dive · 20d ago
- Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trialTyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step toward that goal — although you just might have to sq…endpoints · 20d ago
- Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockTyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premar…fiercebiotech · 20d ago
- Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutInfectious-disease biotech Invivyd has appointed its current chairman, Marc Elia, as CEO.fiercebiotech · 26d ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that